A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

Completed

Conditions studied: Hereditary Angioedema

In brief

Patients with HAE Type I or II who enroll in the study are asked to complete a patient diary when they experience an HAE attack. If icatibant is taken as the first treatment for the attack, the patient diary will ask questions over a 48 hour period after dosing to track the characteristics and severity of the attack along with the patient's level of anxiety.

Key facts

Study ID
NCT07009262
Run by
KalVista Pharmaceuticals, Ltd.
People needed
88
Starts
2025-04-21
Expected to finish
2025-11-25
Last updated by the study team
2026-01-13

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.